Recent News

• 03.30.2026 - DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights
• 03.23.2026 - DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026
• 03.05.2026 - DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia
• 02.24.2026 - DiaMedica Therapeutics to Participate in Upcoming March Investor Conferences
• 01.16.2026 - DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 12.18.2025 - DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDA
• 11.12.2025 - DiaMedica Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights

Recent Filings

• 03.30.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 02.17.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.17.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.06.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 01.06.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.06.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.06.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.05.2026 - 8-K Current report
• 12.18.2025 - 8-K Current report
• 12.18.2025 - EX-99.1 EX-99.1